Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Seres Therapeutics will collaborate with the Mayo Clinic’s Center for Individualized Medicine to develop microbiome-based therapeutics for liver diseases. The partners will look for treatments for primary sclerosing cholangitis, a bile duct disorder, and study the role of the microbiome in nonalcoholic steatohepatitis. Separately, Vedanta Biosciences, another firm trying to develop therapeutics to modulate the microbiome, has raised $50 million. The funding round, which will support several clinical studies, was led by PureTech, Rock Springs Capital, Invesco Asset Management, and Health for Life Capital.
This article has been sent to the following recipient: